| Michael Mclaughlin, DO | |
|
1401 Sw 34th St Ste 200, Moore, OK 73160-3059 | |
| (405) 945-4359 | |
| (405) 644-5424 |
| Full Name | Michael Mclaughlin |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 15 Years |
| Location | 1401 Sw 34th St Ste 200, Moore, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376779231 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 4929 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Integris Health Edmond | Edmond, OK | Hospital |
| Integris Southwest Medical Center | Oklahoma city, OK | Hospital |
| Integris Baptist Medical Center, Inc | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integris Ambulatory Care Corporation | 2365408465 | 382 |
News Archive
Isilon® Systems today announced that Kyoto University's Department of Diagnostic Imaging and Nuclear Medicine has implemented Isilon's scale-out NAS for a new collaboration project focused on identifying new technologies and enhanced functionality in diagnostic imaging. With Isilon IQ, the Department has unified ultrasonic tomography, retinal tomography and MRI image data into a single, highly scalable, high performance, shared pool of storage to accelerate time-to-results for its mission-critical research.
Factors such as low hemoglobin levels, increased systolic blood pressure, and male gender are linked to a higher risk of silent cerebral infarcts (SCIs), or silent strokes, in children with sickle cell anemia (SCA), according to results from a large, first-of-its-kind study published online today in Blood, the Journal of the American Society of Hematology (ASH).
Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.
Today, at the International Conference on Advanced Technologies & Treatments for Diabetes 2020, Ascensia presented data from a study that assessed the performance of blood glucose monitoring systems when used with mobile applications (apps) for diabetes management.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.
› Verified 4 days ago
| Entity Name | Integris Ambulatory Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750333936 PECOS PAC ID: 2365408465 Enrollment ID: O20041209000354 |
News Archive
Isilon® Systems today announced that Kyoto University's Department of Diagnostic Imaging and Nuclear Medicine has implemented Isilon's scale-out NAS for a new collaboration project focused on identifying new technologies and enhanced functionality in diagnostic imaging. With Isilon IQ, the Department has unified ultrasonic tomography, retinal tomography and MRI image data into a single, highly scalable, high performance, shared pool of storage to accelerate time-to-results for its mission-critical research.
Factors such as low hemoglobin levels, increased systolic blood pressure, and male gender are linked to a higher risk of silent cerebral infarcts (SCIs), or silent strokes, in children with sickle cell anemia (SCA), according to results from a large, first-of-its-kind study published online today in Blood, the Journal of the American Society of Hematology (ASH).
Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.
Today, at the International Conference on Advanced Technologies & Treatments for Diabetes 2020, Ascensia presented data from a study that assessed the performance of blood glucose monitoring systems when used with mobile applications (apps) for diabetes management.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Mclaughlin, DO 5300 N Independence Ave, Suite 280, Oklahoma City, OK 73112-5556 Ph: (405) 945-4359 | Michael Mclaughlin, DO 1401 Sw 34th St Ste 200, Moore, OK 73160-3059 Ph: (405) 945-4359 |
News Archive
Isilon® Systems today announced that Kyoto University's Department of Diagnostic Imaging and Nuclear Medicine has implemented Isilon's scale-out NAS for a new collaboration project focused on identifying new technologies and enhanced functionality in diagnostic imaging. With Isilon IQ, the Department has unified ultrasonic tomography, retinal tomography and MRI image data into a single, highly scalable, high performance, shared pool of storage to accelerate time-to-results for its mission-critical research.
Factors such as low hemoglobin levels, increased systolic blood pressure, and male gender are linked to a higher risk of silent cerebral infarcts (SCIs), or silent strokes, in children with sickle cell anemia (SCA), according to results from a large, first-of-its-kind study published online today in Blood, the Journal of the American Society of Hematology (ASH).
Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.
Today, at the International Conference on Advanced Technologies & Treatments for Diabetes 2020, Ascensia presented data from a study that assessed the performance of blood glucose monitoring systems when used with mobile applications (apps) for diabetes management.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.
› Verified 4 days ago